Skip to content

A prospective, double-blind, randomized controlled study of the effects of esketamine anesthesia on intraoperative physiology and early postoperative recovery quality in elderly patients

A prospective, double-blind, randomized controlled study of the effects of esketamine anesthesia on intraoperative physiology and early postoperative recovery quality in elderly patients

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074599
Enrollment
Unknown
Registered
2023-08-10
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients over 65 years of age undergoing spinal surgery under tracheal intubation and general anesthesia

Interventions

Esketamine group(K Group):Esketamine and other drugs were used for anesthesia
Saline control group:Saline and other drugs were used for anesthesia,but not Esketamine.

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 65 years of age who were scheduled for spinal surgery under general anesthesia with tracheal intubation, with an expected duration of surgery greater than 1 hour, volunteered to participate and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe bradycardia (2) patients with contraindications to esmketamine, such as patients with serious risk of elevated blood pressure or intracranial pressure; People with poorly controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure > 180/100 mmHg); Pre-eclampsia and eclampsia; People with untreated or under-treated hyperthyroidism (hyperthyroidism) (3) overt ischemic heart disease; Congestive heart failure; Severe liver and kidney dysfunction; Have or have had a history of a serious mental disorder; Increased intracranial pressure and central nervous system injury or disease; Glaucoma; Previous history of alcohol and drug abuse. (4) hearing or language impairment, or inability to cooperate with the neurocognitive assessment for other reasons

Design outcomes

Primary

MeasureTime frame
QoR-15 score;

Secondary

MeasureTime frame
heart rate and blood pressure;Use of vasoactive drugs and atropine;RASS sedation score;Recovery room residence time;postoperative hospital stay;

Countries

China

Contacts

Public ContactXiaoxing Chen

Guangdong Provincial Hospital of Chinese Medicine

172300186@qq.com+86 137 1933 4529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026